Streetbeat News

Price Targets

CAMP

Roth MKM analyst Scott Searle maintains a 'Buy' rating on CalAmp (NASDAQ:CAMP) but has lowered the price target from $6 to $5.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 1:13 pm

MGRC

Oppenheimer analyst Scott Schneeberger has maintained an Outperform rating on McGrath RentCorp (NASDAQ:MGRC) and raised the price target from $114 to $116.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 1:03 pm

CMMB

Roth MKM analyst Dylan Dupuis has initiated coverage on Chemomab Therapeutics (NASDAQ:CMMB) with a Buy rating and a price target of $7.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:56 pm

TSX:KXS

BMO Capital analyst Thanos Moschopoulos maintains an Outperform rating on Kinaxis (TSX:KXS) but lowers the price target from C$215 to C$190.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:55 pm

DTE

BMO Capital analyst James Thalacker has maintained a 'Market Perform' rating on DTE Energy (NYSE:DTE) but lowered the price target from $125 to $106.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:53 pm

HRTG

Piper Sandler analyst Paul Newsome has maintained a Neutral rating on Heritage Insurance Holdings (NYSE:HRTG) and lowered the price target from $6.35 to $5.7.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:53 pm

HR

BMO Capital analyst Juan Sanabria maintains a Market Perform rating on Healthcare Realty Trust (NYSE:HR) and lowers the price target from $20 to $17.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:48 pm

NGD

BMO Capital analyst Brian Quast has maintained an 'Outperform' rating on New Gold (TSX:NGD) and raised the price target from C$2 to C$2.25.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:46 pm

ZION

Piper Sandler analyst Brad Milsaps assumes Zions Bancorp (NASDAQ:ZION) with a Neutral rating and announces a price target of $34.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:44 pm

MRTX

BMO Capital analyst Evan David Seigerman has maintained a 'Market Perform' rating on Mirati Therapeutics (NASDAQ:MRTX) and raised the price target from $31 to $72.

Portfolio Pulse from Benzinga Newsdesk

October 06, 2023 | 12:43 pm